期刊文献+

替米沙坦改善高血压患者的胰岛素抵抗 被引量:6

原文传递
导出
摘要 目的观察替米沙坦对高血压患者胰岛素抵抗的影响。方法入选初诊为原发性高血压患者110例为研究对象,同期年龄和性别相匹配的健康体检者100例为对照组。高血压患者给予替米沙坦40~80mg/d,治疗12周。观察高血压患者治疗前后血压、空腹血糖和胰岛素(FINS)、胰岛素敏感指数(ISI)和胰岛素抵抗指数(HOMA-IR)水平的变化。结果治疗前高血压患者血压、FINS和HOMA-IR水平明显高于对照组,ISI水平明显低于对照组(均P<0.05)。替米沙坦治疗12周后,高血压患者的血压明显下降,空腹血糖、FINS和HOMA-IR水平降低,ISI水平升高(均P<0.05)。结论替米沙坦可改善高血压患者的胰岛素抵抗。
出处 《中华高血压杂志》 CAS CSCD 北大核心 2012年第1期78-80,共3页 Chinese Journal of Hypertension
  • 相关文献

参考文献19

  • 1Deedwania P.Hypertension,dyslipidemia,and insulin resistance in patients with diabetes mellitus or the cardiometabolic syn-drome:benefits of vasodilatingβ-blockers[J].J Clin Hypertens(Greenwich),2011,13(1):52-59.
  • 2Whelton PK.Hypertension in diabetes mellitus[J].Endocrinol Nutr,2009,56(Suppl 4):63-66.
  • 3Ko SH,Cao W,Liu Z.Hypertension management and microvas-cular insulin resistance in diabetes[J].Curr Hypertens Rep,2010,12(4):243-251.
  • 4陈正迪.替米沙坦对高血压患者纤溶功能的影响[J].中华高血压杂志,2011,19(6):581-583. 被引量:3
  • 5黄国秀,余文珊,伍广伟,谭文芳,李建英,叶伟林,温建东,陈健.替米沙坦对肥胖性高血压患者体脂、血脂及胰岛素抵抗的影响[J].山东医药,2011,51(4):13-15. 被引量:6
  • 6Nissen SE,WolskiK.Effect of rosiglitazone on the risk of myo-cardial infarction and death from cardiovascular causes[J].N Eng J Med,2007,356(24):2457-2471.
  • 7李杰,赵卫华,胡健.替米沙坦对胰岛素抵抗大鼠糖脂代谢和抵抗素表达的影响[J].山东医药,2009,49(24):30-32. 被引量:6
  • 8Bahadir O,Uzunlulu M,Oguz A,et al.Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome[J].Hypertens Res,2007,30(1):49-53.
  • 9Benson SC,Pershadsingh HA,Ho CI,et al.Identification of telmisartan as a unique angiotensinⅡ:receptor antagonist with selective PPAR(gamma)-modulating activity[J].Hypertension,2004,43(5):993-1002.
  • 10Yamagishi S,Takeuchi M.Telmisartan is a promising cardio-metabolic sartan due to its unique PPAR-γinducing property[J].Med Hypotheses,2005,64(3):476-478.

二级参考文献47

共引文献19

同被引文献46

  • 1Armas - Herndndez M J, Herndndez - Herndndez R, Armas - Padil- la MC,et al. Fibrinolytic system in normotensive subjects and hy- pertensive patients[J]. Am J Ther, 2007,14(2) : 177 - 182.
  • 2范慧霞.中药丹参药理作用研究概况[J].新疆中医药,2007,25(5):113-117. 被引量:43
  • 3Benson S C,Pershadsingh H A,HO C I, et al. Identifica- tion of teimisartan as a unique angjotensin : receptor antag- onist withseing activity [ J ]. Hyperension, 2012,6 (5) : 993-1002.
  • 4Fujisaka S, Usi I, Kanatani Y, et al. Telmisartan improves insulinresi stance and modulates adipose tissue macro- phage polarizgtion in high-fed mice [ J ]. Endocrinology, 2011,152 (5) : 1789-1799.
  • 5Kobayashi K, Ohno Y, Takeaka T, et al. Telmisartan low- ers home blood pressure and improvrs insuin resistance without correlation between their changes [ J ]. Clin Exp Hypertens ,2011,33 (2) : 100-105.
  • 6李娟,陈玲,张晓琳,等.红景天、蛹虫草、大黄配伍治疗代谢综合征的实验研究Ⅰ-改善胰岛素抵抗作用[J].中医杂志,2012,37(6):27-29.
  • 7Kobayashi K, Ohno Y, Takeaka T, et al. Telmisartan lowers home blood pressure and improvrs insuin resistance without correlation between their changes [ J ]. Clin Exp Hypertens, 2011,33 ( 2 ) : 100 - 105.
  • 8Benson SC,Pershadsingh HA,Ho CI. Identification of telmisartan as a unique angiotensin Ⅱreceptor antagonist with selective PPARgamma-modulating activity[J].Hypertension,2004.993-1002.
  • 9Weber Ma,Julius S,Kjeldsen SE. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial[J].The Lancet,2004.2049-2051.
  • 10McMurray JJ,Holman RR,Haffner SM. Effect of valsartan on the incidence of diabtets and cardiovascular events[J].New England Journal of Medicine,2010.1477-1490.

引证文献6

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部